Al-Habsi Khalid, Al-Khabori Murtadha, Al-Muslahi Muhanna, Pathare Anil, Al-Farsi Khalil, Al-Huneini Mohammed, Al-Lamki Sulayma, Al-Kindi Salam
Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman.
Oman Med J. 2015 Mar;30(2):111-4. doi: 10.5001/omj.2015.24.
To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab.
We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria.
Nineteen patients (59%) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14-58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59% (complete response 44%, partial response 15%) and the median time to respond was 30 days with a response rate of 44% at four weeks. In all responders, the cumulative rate of loss of response was 32% with a median time to lose response of 54 months.
The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended.
评估接受利妥昔单抗治疗的慢性免疫性血小板减少症（ITP）患者的缓解率和缓解持续时间。
我们回顾性分析了阿曼两个三级中心连续治疗的32例慢性ITP患者。缓解评估基于美国血液学会标准。
19例患者（59%）有初始缓解。然而，这19例患者中有6例失去缓解，13例患者获得持久缓解。诊断时的中位年龄为25岁（范围14 - 58岁）。从诊断到利妥昔单抗治疗的中位时间为21个月。开始使用利妥昔单抗后的中位随访时间为26个月。总体累积缓解率为59%（完全缓解44%，部分缓解15%），中位缓解时间为3天，四周时缓解率为44%。在所有缓解者中，缓解丧失的累积率为32%，中位缓解丧失时间为54个月。
利妥昔单抗用于ITP可实现高缓解率和长缓解持续时间。我们的研究受样本量小的限制，建议进一步开展更大规模的前瞻性研究。
